Serum ready for Covishield rollout as soon as it receives DCGI nod
World's biggest vaccine maker has already manufactured over 50 million doses; further production will start as soon as it gets necessary approvals in India and the UK. SII is hoping to supply 3 billion doses of vaccine in 2021

- Dec 24, 2020,
- Updated Dec 24, 2020 1:41 PM IST
Serum Institute of India, which is manufacturing one of the top three vaccine candidates in India, is ready for the vaccine rollout as soon as it receives a green signal from the drug regulatory authority. The world's biggest vaccine maker has already manufactured over 50 million doses of the vaccine, which is developed by Oxford University and Swedish-British pharma major AstraZeneca.
Further production will start as soon as it gets necessary approvals in India and the UK. They are hoping to supply 3 billion doses of the vaccine in 2021.
The vaccine maker is also working with the government to prepare a distribution plan. "Everything is ready for rollout; we are only waiting for regulator's review... which city will get the vaccine first depends on the government," The Economic Times quoted an official as saying.
Serum Institute of India, which is manufacturing one of the top three vaccine candidates in India, is ready for the vaccine rollout as soon as it receives a green signal from the drug regulatory authority. The world's biggest vaccine maker has already manufactured over 50 million doses of the vaccine, which is developed by Oxford University and Swedish-British pharma major AstraZeneca.
Further production will start as soon as it gets necessary approvals in India and the UK. They are hoping to supply 3 billion doses of the vaccine in 2021.
The vaccine maker is also working with the government to prepare a distribution plan. "Everything is ready for rollout; we are only waiting for regulator's review... which city will get the vaccine first depends on the government," The Economic Times quoted an official as saying.